



2024 Recommended Adult Immunization Schedule (Maintains CPP Eligibility)

Manufacturer	Brand Name	Vaccine	Age	19-26 yrs	27-49 yrs	50-64 yrs	65-74 yrs	> 75 yrs	
Pfizer Moderna Novavax	Comirnaty® Spikevax™ COVID-19	COVID-19		1 or more doses of updated vaccine					
Seqirus Sanofi	Afluria® Flucelvax® Fluad® Fluzone® Fluzone High Dose® Flublok®	Influenza inactivated (IIV) Influenza recombinant (RIV)		1 dose annually					
OR				OR					
AstraZeneca	FluMist®	Influenza (LAIV)		1 dose annually					
Pfizer Moderna	Abrysvo® mResvia™	RSV adult & maternal RSV adult		Seasonal administration during each pregnancy		1 dose		1 dose	
Sanofi	Tenivac® Adacel®	Tetanus, Diphtheria Tetanus, Diphtheria, Pertussis		1 dose Tdap each pregnancy; 1 dose Td/Tdap for wound management					
				1 dose Tdap, then Td or Tdap booster every 10 years					
Merck	MMRII®	Measles, Mumps, Rubella		1 or 2 doses depending on indication (if born 1957 or later)			For healthcare personnel		
Merck	Varivax®	Varicella		2 doses (if born 1980 or later)		2 doses			
GSK	Shingrix®	Zoster recombinant (RZV)		2 doses for immunocompromising conditions			2 doses		
Merck	Gardasil 9®	Human Papillomavirus (HPV)		2 or 3 doses depending on age at initial vaccination	27-45 years				
Pfizer Merck	Pevnar 20® Capvaxive™ Vaxneuvance® Pneumovax 23®	Pneumococcal (PCV20) Pneumococcal (PCV21) Pneumococcal (PCV15) Pneumococcal (PPSV23)						1 dose PCV20 or PCV21 - OR - 1 dose PCV15 followed by 1 dose PPSV23	
Merck	Vaqta®	Hepatitis A		2, 3 or 4 doses depending on vaccine					
Merck Dynavax	Recombivax HB® Hepelisav-B®	Hepatitis B		2, 3 or 4 doses depending on vaccine or condition					
Sanofi Pfizer	MenQuadfi® Penbraya™ ●	MenACWY MenABCWY		1 or 2 doses depending on indication, see notes for booster recommendations					
Pfizer	Trumenba® Penbraya™ ●	MenB MenABCWY		19-23 years	2 or 3 doses depending on vaccine and indication, see notes for booster recommendations				
Sanofi	ActHIB®	Haemophilus Influenzae Type B		1 or 3 doses depending on indication					
	JYNNEOS Vaccine	Monkeypox							



Range of
Recommended Ages



High risk
Population



Non-high-risk groups may
receive vaccine, subject to
shared clinical decision making